Roy Jacobs & Associates announces that it is investigating SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) (NASDAQ: SCLN), a specialty pharmaceutical company, for potentially violating the federal securities laws by issuing false and misleading statements to its shareholders.

For further information, please contact Roy L. Jacobs, Esq. toll-free at 1-888-884-4490 or by e-mail at rjacobs@jacobsclasslaw.com.

SciClone revealed that the Securities and Exchange Commission (“SEC”) has informed the Company that the SEC has initiated a formal, non-public investigation of SciClone. The Company has also been contacted by the Department of Justice (“DOJ”), which requested that the Company meet with the DOJ regarding its compliance with the Foreign Corrupt Practices Act (“FCPA”). On this news, shares of SciClone plunged 29% to $2.48. The FCPA prohibits a company from making illicit payments to foreign officials to obtain a business advantage.

If you have information that would assist Roy Jacobs & Associates in its investigation or you are interested in discussing your rights free of charge, please contact Roy L. Jacobs. Mr. Jacobs will be glad to personally speak with you.

Copyright Business Wire 2010